Marvin L. White - Mar 2, 2024 Form 4 Insider Report for Aptevo Therapeutics Inc. (APVO)

Role
President and CEO, Director
Signature
/s/ SoYoung Kwon, Attorney-in-Fact
Stock symbol
APVO
Transactions as of
Mar 2, 2024
Transactions value $
$0
Form type
4
Date filed
3/5/2024, 04:06 PM
Previous filing
Jan 30, 2024
Next filing
May 28, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APVO Common Stock Options Exercise +12.9K +28.75% 57.8K Mar 2, 2024 Direct F1
transaction APVO Common Stock Options Exercise +9.58K +16.57% 67.4K Mar 3, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APVO Restricted Stock Unit Options Exercise $0 -12.9K -33.33% $0.00 25.8K Mar 2, 2024 Common Stock 12.9K Direct F1, F2
transaction APVO Restricted Stock Unit Options Exercise $0 -9.58K -50% $0.00 9.58K Mar 3, 2024 Common Stock 9.58K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2 On March 3, 2023, the reporting person was granted 38,750 RSUs, vesting in three approximately equal annual installments beginning on March 2, 2024.
F3 On June 7, 2022, the reporting person was granted 28,750 RSUs, vesting in three approximately equal annual installments beginning on March 3, 2023.